IT Starts With SITC Membership

LEARN:

Participate in low- or zero-cost educational programming

CONNECT:

Networking and volunteer opportunities to accelerate your career growth

PUBLISH:

Low-or zero-cost processing fees for articles accepted to the Journal for ImmunoTherapy of Cancer (JITC)

ENGAGE:

Numerous opportunities to showcase your research through funding, awards and abstracts

Immunotherapy Resources

40^th Anniversary Annual Meeting & Pre-Conference programs

As the largest conference focused solely on cancer immunotherapy, the SITC Annual Meeting & Pre-Conference Programs provides international leaders from academia, regulatory and government agencies, as well as industry representatives, with a multidisciplinary educational and interactive environment focused on improving outcomes for all cancer patients. If you are a researcher, clinician or student in a non-Industry/Biotech setting, and you reside and work/study in a developing economy according to the World Bank, you may be eligible for zero-cost registration to the SITC Annual Meeting & Pre-Conference Programs.

Learn More

Targets for Cancer IO: A Deep Dive Series

SITC is pleased to host its fifth Targets for Cancer IO: A Deep Dive Series. This new series will include six live webinars addressing various hot topics in immuno-oncology. Key leaders in the field will provide an overview of the current state of the science and address questions about its future. 

Explore the Series

Advances in Cancer Immunotherapy™

The Advances in Cancer Immunotherapy™ (ACI) educational series offers focused clinical education on a disease state or topic. Attendees of these half-day, innovative programs get in-depth training in immunotherapy treatment for a variety of topics from experts in the field. The ACI program also features discussions of closed cases submitted from attendees to hear guidance and insights from faculty. These programs are available at zero cost to the attendee.

LEARN MORE

Cancer immunotherapy clinical practice guidelines

The SITC Cancer Immunotherapy Guidelines program is a collection of Clinical Practice Guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations on when and how to use immunotherapy to help improve outcomes for patients with cancer.

Discover CPGs

Certificate in Cancer Immunotherapy

The Certificate in Cancer Immunotherapy is offered online via the SITC connectED platform and consists of eight independent learning modules—all approved for CME, CNE, CPE and MOC credits—that can be stacked to earn the SITC Graduate in Cancer Immunotherapy (SITC-G) designation. The SITC-G designation identifies a healthcare provider as completing specialized training in cancer immunotherapy. The SITC-G designation certificate is available to those that are treating physicians (U.S. licensed MD / DO or global equivalent), or practicing licensed NP, PA, PharmD or RPh degree holders involved in direct clinical services, or global equivalent. For learners that do not meet the parameters above, a non-designation certificate track is available, for those who wish to further their immunology/immunotherapy education. Non-designation certificate learners are able to earn CME, CNE, CPE and MOC credit (as available in each module). Each module is available individually. This program is available at zero cost to members residing in low- and lower middle- income countries. 

Discover the Certificate in Cancer Immunotherapy

AI in IO: SITC-NCI Computational Immuno-oncology Webinar Series

In partnership with and partial funding by the National Cancer Institute (NCI), is pleased to launch our fifth iteration of the "SITC-NCI Computational Immuno-oncology Webinar Series" throughout April-December 2025. This year's series will focus specifically on advanced methods and clinical utility for biomarker development in IO. These ten free-to-attend digital events will help individual research labs to embrace the computational challenges of analyzing and integrating diverse assay data across the spectrum of immuno-oncology for biomarker development.

Explore the Series

INCREASING ACCESS TO IO: A GLOBAL WEBINAR SERIES

SITC is pleased to launch this free-to-attend educational program crafted specifically for international audiences, titled “Increasing Access to IO: A Global Webinar Series”. This series will serve as an excellent resource for all stakeholders interested in learning about the application of immunotherapy, as well as the infrastructure and resources needed to support the expansion of access around the globe.

LEARN MORE

Cancer Immunotherapy winter school

Tailored to early-to-mid career scientists and clinicians in the field of cancer immunotherapy working in academic, clinical, industry and government settings, this hybrid program provides the best in cancer immunotherapy education taught by leading experts in the field.

Winter School participants gain a deep understanding of the core principles of tumor immunology and cancer immunotherapy, and developing areas in the field including biomarker technology, validation and clinical integration, clinical trial design, data analysis and considerations for combination therapies.

Learn More

Journal for ImmunoTherapy of Cancer

The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). This open access, peer-reviewed journal not only serves as the global voice of the society, but also a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy–from basic research to clinical application. 

JITC offers full waivers for the full Article Processing Charges (APC)–100% discount of the APC–where all authors are based in low-income countries. Requests for waivers must be made prior to submission.

Explore the Journal

Upcoming Events

If you are interested in learning more about upcoming SITC events and collaborative education programs, please visit the SITC event calendar.  

Global Access and Impact Committee

In 2018, the Society for Immunotherapy of Cancer (SITC) Board of Directors prioritized global access to cancer immunotherapy as a strategic goal for the society. To facilitate this goal, SITC formed the Global Access and Impact Committee. This committee, comprising an array of international stakeholders, seeks to develop strategies that overcome the challenges of science, education, policy and infrastructure within low- and lower-middle income economies to promote immunotherapy utilization and access across the world.